ASX Announcement
28 October 2026

Results of Buy-back

Tissue Repair Limited (ASX: TRP) ('**TRP'** or 'the **Company'**) advises that its off-market equal access share buy-back (**Buy-Back**) closed at 5:00pm (AEDT) on 27 October 2026.

Valid Applications were received from 172 Eligible Shareholders in respect of 7,198,783 shares under the Buy-Back.

As the number of shares the subject of valid Applications did not exceed the Buy-Back Limit of 7,692,307 Shares, no Scale-Back will apply, and all valid Applications will be accepted in full.

Accordingly:

- the Company will buy back 7,198,783 Shares under the Buy-Back;
- the aggregate buy-back consideration payable by the Company will be $935,841.79;
- the Buy-Back is expected to occur on 29 October 2026; and
- payment to participating Eligible Shareholders is expected to be made on or around 30 October 2026.

The Company has today lodged an Appendix 3C (Final Buy-Back Notification) with the ASX in relation to the Buy-Back.

Authorised for release by the Board of the Company.

Tony Charara
Chief Executive Officer
1300 736 573
tony.charara@mable.com.au

For personal use only

About Tissue Repair

About Tissue Repair Tissue Repair Limited (ASX:TRP) is a Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987®, with a secondary focus on commercialising TR Pro+® a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures, as well as other acute wound products in its pipeline. The Company's longer-term strategy is to commercialise its propriety Glucoprime® API to treat a variety of wounds and skin conditions.